Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

被引：24

作者：

Montemorano, Lauren ^{[1
]}

Lightfoot, Michelle D. S. ^{[2
]}

Bixel, Kristin ^{[2
]}

机构：

[1] Ohio State Univ, Dept Obstet & Gynecol, Wexner Med Ctr, Columbus, OH 43210 USA

[2] Ohio State Univ, Wexner Med Ctr, James Canc Hosp, Dept Obstet & Gynecol,Div Gynecol Oncol, Columbus, OH 43210 USA

来源：

ONCOTARGETS AND THERAPY | 2019年 / 12卷

关键词：

olaparib; PARP inhibitor; ovarian cancer; maintenance; DOUBLE-BLIND; THERAPY; CHEMOTHERAPY; BEVACIZUMAB; INHIBITORS; CARCINOMA;

D O I：

10.2147/OTT.S195552

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. In this review, we focus on the use of olaparib in the maintenance setting including the evidence to date, ongoing research, and future directions.

引用

页码：11497 / 11506

页数：10

共 50 条

[41] Maintenance Olaparib for Metastatic Pancreatic Cancer
Charkes, N. David
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (15): : 1491 - 1491
[42] Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
Bangham, Madeleine
Goldstein, Robert
Walton, Henry
Ledermann, Jonathan A.
GYNECOLOGIC ONCOLOGY REPORTS, 2016, 18 : 22 - 24
[43] Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
Chen, Qian
Li, Xiaoli
Zhang, Zhen
Wu, Tong
FRONTIERS IN ONCOLOGY, 2022, 12
[44] Olaparib Approved for Advanced Ovarian Cancer
不详
CANCER DISCOVERY, 2015, 5 (03) : 218 - 218
[45] Olaparib recommendations for ovarian cancer patients
Johnson, Peter
FUTURE ONCOLOGY, 2016, 12 (02) : 149 - 151
[46] Olaparib is efficacious in patients with ovarian cancer
Nature Reviews Clinical Oncology, 2015, 12 (2) : 64 - 64
[47] Olaparib in ovarian cancer with BRCA mutation
Pujade-Lauraine, Eric
Combe, Pierre
BULLETIN DU CANCER, 2015, 102 (06) : S82 - S84
[48] COST-EFFECTIVENESS OF NIRAPARIB VERSUS ROUTINE SURVEILLANCE AND OLAPARIB FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH OVARIAN CANCER IN THE UNITED STATES
Fisher, M.
Guy, H.
Walder, L.
VALUE IN HEALTH, 2018, 21 : S32 - S32
[49] NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer
Tucker, Helen
Charles, Zoe
Robertson, Janet
Adam, Jane
LANCET ONCOLOGY, 2016, 17 (03): : 277 - 278
[50] Olaparib, a new hope for ovarian cancer
Samoon, Zarka
Jabbar, Adnan Abdul
INDIAN JOURNAL OF CANCER, 2020, 57 (03) : 346 - 347

← 1 2 3 4 5 →